Korea Arlico Pharm알리코제약
260660 · KOSDAQ · ₩260660 · 알리코제약
₩1,864▼ ₩16 (0.85%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 51.0% | 51.8% | 52.4% | 58.9% | 63.7% | 62.5% |
| Operating margin | −4.1% | 0.5% | −2.7% | 1.6% | 5.9% | 3.4% |
| Net margin | −1.5% | −0.3% | −2.8% | 1.6% | 4.8% | 3.5% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −2.7% | +5.7% | +1.8% | +11.6% | +19.7% | — |
| Operating income growth | −910.3% | +119.2% | −267.9% | −68.9% | +105.8% | — |
| Net income growth | −371.0% | +88.7% | −275.0% | −61.9% | +63.0% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −3.7% | −0.8% | −6.4% | 3.4% | 9.5% | 6.1% |
| Return on assets | −1.7% | −0.4% | −3.1% | 1.9% | 5.9% | 4.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 125.0% | 119.7% | 116.3% | 94.8% | 73.4% | 49.2% |
| Net debt to equity | −15.4% | −6.7% | −4.1% | 17.2% | 5.8% | −3.3% |
| Current ratio | 103.3% | 112.1% | 113.5% | 118.8% | 143.4% | 203.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Korea Arlico Pharm / 알리코제약 / 260660 / KRX:260660
Source: KRX statistical information